Alzinova AB is Swedish biotechnology enterprise engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The company was founded in 2011 by the inventors of the AβCC peptide™ technology (patent pending) and MIVAC Development AB in close collaboration with the holding company at the University of Gothenburg in Sweden, GU Ventures AB.
The proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities towards several ends, including the discovery and development of novel therapeutics, research tools and services that enhance productivity within Alzheimer’s disease research. Alzinova is exploiting the unique properties of this non-fibrillogenic technology to develop therapeutics and diagnostics otherwise unavailable when using fibrillogenic peptides. The company focuses on development of a unique highly specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Alzheimer’s disease is a therapeutic area in dire need of effective treatments. The disease, which primarily afflicts the elderly (65+), irreversibly destroys brain cells and, by so doing, affects the patient’s cognitive ability. Early symptoms typically include memory lapses, mood swings, and difficulty in finding words for everyday objects. As the disease progresses, symptoms become worse and the patient is likely to eventually require round-the-clock monitoring in a nursing home. The disease slowly kills the patient in a process that, on average, amounts to 7 years.
There are no disease modifying therapies available for this ailment, which currently afflicts on the order of 33 million people worldwide. According to the World Alzheimer Report 2015, the total annual cost for all dementia is currently $818 billion, and is projected to become a “trillion dollar disease” by 2018. Alzheimer’s disease constitutes approximately 60-80% of all dementia, and therefore accounts for most of this cost. Due to a growing and ageing global population, 52 million Alzheimers cases are estimated by the year 2030 and 92 million by 2050. Therapeutics which exhibit even moderate efficacy will hence not only enhance the quality of life for tens of millions of people (and their families and friends), but also generate substantial savings for society.